Abstract
This report analyzes the worldwide markets for Drug Discovery Technologies in
Millions of US$. The specific technology types analyzed are Bioanalytical
Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics, and Other Drug Discovery Technologies
(Include Combinatorial Chemistry, Nanotechnology and RNAi). The report
provides separate comprehensive analytics for the US, Canada, Japan, Europe
and Rest of World. Annual forecasts are provided for each region for the
period of 2001 through 2015. The report profiles 187 companies including many
key and niche players worldwide such as Abbott Laboratories, Affymetrix Inc.,
Agilent Technologies Inc., Albany Molecular Research, Inc., Amersham
Biosciences, Applera Corporation, ArQule Inc., AstraZeneca, BD Biosciences,
Bio-Rad Laboratories, Inc., BioSciences Group, Caliper Life Sciences, Inc.,
Capital GenomiX, Caprion Pharmaceuticals Inc., Charles River Laboratories
International, Inc., ChemBridge Corporation, deCODE Genetics, Inc., Evotec AG,
Galapagos NV, Incyte Corporation (Formerly Incyte Genomics, Inc.), Infinity
Pharmaceuticals, Inc., Invitrogen Corporation, Medarex, Inc., Merck & Co.,
Inc., Millennium Pharmaceuticals, Inc., National Center for Drug Screening,
PerkinElmer, Inc., Pharmacopeia Inc., Proteome Systems, Quantum
Pharmaceuticals, Shimadzu Corporation, Sigma-Aldrich, Tecan Group, Thallion
Pharmaceuticals, Inc. and Tripos, International. Market data and analytics are
derived from primary and secondary research. Company profiles are mostly
extracted from URL research and reported select online sources.
| 
View Cart
